According to a report by Intel Market Research, the global Pyrazinamide API Market was valued at USD 142.2 million in 2025 and is estimated to reach USD 146.8 million in 2026. The market is projected to reach USD 188.0 million by 2034, representing a 3.14% CAGR during 2026–2034. Pyrazinamide is a first-line tuberculosis API used at relatively high daily doses during the intensive phase of drug-susceptible TB treatment and in selected other TB regimens. Its high dose intensity and role in global public-health procurement make API tonnage significant despite mature generic pricing.

Explore the full report: Pyrazinamide API Market Report

Why Is Demand Increasing?

• High dose intensity supports API volumes: Pyrazinamide is administered at materially higher daily mass than isoniazid in standard TB treatment, making it a significant API input during the intensive phase.

• Persistent global TB burden: WHO estimated 10.7 million incident TB cases in 2024, maintaining substantial first-line treatment requirements and supporting continued procurement.

• Fixed-dose combinations remain central: High-burden countries continue to use first-line FDCs to simplify treatment and adherence, supporting recurring demand for pyrazinamide API.

Tuberculosis Treatment API Industry Watch

The Pyrazinamide API industry remains closely connected to global tuberculosis treatment programs, particularly intensive-phase therapy and fixed-dose combinations. Asia-Pacific leads both manufacturing and treatment-linked demand, supported by the concentration of WHO-prequalified suppliers in India and the high TB burden across South-East Asia and the Western Pacific. The report identifies four current quality-assured API suppliers, with Resonance Specialities becoming the newest source in August 2026. Competition is centered on WHO prequalification, high-volume synthetic economics, moisture control, particle properties and long-term global-health supply. Granular and particle-controlled grades can improve flow and blending in high-dose tablets and FDCs. Meanwhile, gradual TB-incidence declines and mature commodity pricing limit faster value expansion.

Segmentation Highlights

• By Type: Standard Crystalline API and Granular/Particle-Controlled API. Standard crystalline API accounts for the largest volume, while processing grades support formulation-specific programs requiring improved flow and blending.

• By Application: Drug-Susceptible TB Intensive Phase, Selected Drug-Resistant TB Regimens and Fixed-Dose Combination Programs. Drug-susceptible TB intensive-phase treatment is the dominant demand driver.

• By Formulation Destination: 500 mg Tablets, TB Fixed-Dose Combination Tablets, Pediatric/Dispersible Products and Other Oral Formats.

• By Customer Type: TB Program/FPP Manufacturers, Generic Formulation Manufacturers and Institutional Manufacturers.

• By Procurement Model: Direct Manufacturer Contracts, Global Health/Long-Term Procurement and Distributor/Trader Procurement.

• By Regulatory Destination: WHO-Prequalified/Highly Regulated Markets and Emerging & Other Regulated Markets.

Regional Outlook

• Asia-Pacific leads both API supply and treatment-linked demand. South-East Asia and the Western Pacific together accounted for 61% of global TB incidence in 2024, while three of the four current WHO-prequalified pyrazinamide suppliers are Indian companies.

• North America has a smaller epidemiological burden but maintains regulated single-agent pyrazinamide products. Current U.S. labeling retains the 500 mg tablet format in 2026.

• Europe accounted for 1.9% of global TB incidence in 2024 and maintains stringent anti-TB medicine quality requirements.

• Latin America accounted for 3.3% of global TB incidence in 2024, supporting programmatic but comparatively smaller regional API demand.

• Middle East & Africa accounted for 33.6% of global TB incidence in 2024, supporting substantial demand for high-dose first-line pyrazinamide-containing treatment.

Download the free sample report: Free Pyrazinamide API Market Sample

Why This Market Matters

The Pyrazinamide API Market has a distinctive volume profile because the API is administered at relatively high daily mass during the intensive phase of TB treatment. This creates substantial API consumption per treatment course and supports recurring demand from national tuberculosis programs. Fixed-dose combination products are particularly important because they remain a central procurement format in high-burden countries.

Supply resilience is another important market consideration. The report identifies four current WHO-prequalified pyrazinamide API suppliers: Resonance Specialities, Anuh Pharma, Lupin and Calyx Chemicals & Pharmaceuticals. Resonance became the newest quality-assured source in August 2026, expanding procurement options. Manufacturing economics, moisture protection, physical properties, regulatory qualification and long-term supply continuity remain important competitive factors.

Competitive Landscape

• Resonance Specialities — Received WHO prequalification in August 2026, becoming the newest current quality-assured pyrazinamide API source.

• Anuh Pharma — Maintains a long-standing WHO-prequalified pyrazinamide API source.

• Lupin — Maintains a WHO-prequalified pyrazinamide API within its broader tuberculosis manufacturing platform.

• Calyx Chemicals & Pharmaceuticals — Maintains a long-standing WHO-prequalified pyrazinamide source.

• Other qualified suppliers — Compete on landed cost, dossier quality, manufacturing reliability, change control and support for regulated customers across multiple geographies.

View the full report: Pyrazinamide API Market Report

FAQ

Q: What is the size of the Pyrazinamide API Market?

A: The market was valued at USD 142.2 million in 2025, is estimated at USD 146.8 million in 2026 and is projected to reach USD 188.0 million by 2034, representing a 3.14% CAGR during 2026–2034.

Q: Which region leads the Pyrazinamide API Market?

A: Asia-Pacific leads by manufacturing scale and treatment-linked TB burden. South-East Asia and the Western Pacific together accounted for 61% of global TB incidence in 2024.

Q: What drives Pyrazinamide API demand?

A: Drug-susceptible TB intensive-phase treatment is the dominant demand driver, while high-dose treatment requirements and fixed-dose combination programs support substantial API volumes.

What Does the Full Report Cover?

The full report provides detailed analysis of the Pyrazinamide API Market across six segmentation dimensions: Type, Application, Formulation Destination, Customer Type, Procurement Model and Regulatory Destination. It covers North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa, examining TB burden, API manufacturing concentration, procurement structures and regulatory access. The study evaluates standard versus granular and particle-controlled API, drug-susceptible and selected drug-resistant TB applications, FDC programs, pediatric products and other oral formats. Competitive analysis covers WHO prequalification, high-volume manufacturing economics, moisture control, particle properties, APIMF quality, supply continuity and customer qualification. The report also examines recent supplier developments, regulatory requirements and market dynamics shaping the forecast through 2034.

View the complete report: Complete Pyrazinamide API Market Report

Download the free sample: Free Pyrazinamide API Market Sample

About Intel Market Research

Intel Market Research provides quantified market research covering market sizing and forecasting, segmentation, regional analysis, competitive landscapes, regulatory developments and industry trends. The report page states that its studies combine primary interviews with industry participants and structured analysis of named secondary sources, with market estimates validated before publication.

Contact Details

Website: www.intelmarketresearch.com | Asia-Pacific: +91 9169164321 | Email: help@intelmarketresearch.com